CJC-1295
5mg
CJC-1295 (no DAC) is a 29-residue synthetic analogue of growth hormone-releasing hormone (GHRH). Research has studied its ability to raise plasma growth hormone and IGF-1 through sustained pulsatile release, helped by a D-Ala substitution at position 2 that gives it a longer half-life than native GHRH. It is most often paired with Ipamorelin in GH-secretagogue research. Supplied as lyophilised powder and released against a third-party HPLC certificate on this page. In-vitro research use only.
Published research on CJC-1295 is indexed on PubMed. See our full UK buyer's guide for CJC-1295.
Intended Use: Strictly for in-vitro laboratory research. Not for use in humans or animals. Not to be used in foods, drugs, or medical diagnostics. This product has not been evaluated by the MHRA or FDA. Buyer assumes full responsibility for safe handling and regulatory compliance.
98%+
Purity
LAB
Certified
SAME
Day Ship
Quantity
Add £19.01 more for free UK delivery
Damaged or lost? Free reshipment guaranteed
CJC-1295 + Ipamorelin 5+5mg
Pre-blended GHRH + GHRP vial: CJC-1295 (no DAC) with Ipamorelin.
All components in a single lyophilised vial. One reconstitution, one inventory line, one CoA.
Research Use Only
This product is intended strictly for research and laboratory use only. Not for human consumption, medical use, or diagnostic purposes.
Certificate of Analysis
Third-party tested
Lyophilised Stability
24 months
Sealed at -20°C, light-protected
Reconstituted Stability
Up to 3 months
Stored at 2-8°C after mixing
Cold-Chain Shipping
Always
Dry-cold pack, Royal Mail Tracked 24
Important Notice
All compounds are sold individually and do not include research supplies. Products are provided in lyophilised (powder) form and require proper reconstitution before use in research settings.
Related Products
Product Specifications
Research Overview
CJC-1295 (no DAC), also called modified GRF 1-29, is a synthetic analogue of growth hormone releasing hormone (GHRH). It binds GHRH receptors in the anterior pituitary to prompt the synthesis and release of growth hormone. The no-DAC form omits the maleimidopropionic acid linker carried by the DAC (Drug Affinity Complex) version, and that shorter half-life yields a more pulsatile pattern of GH release, one researchers regard as closer to natural endogenous secretion. That physiological character is what makes it valuable for studies needing realistic GH release kinetics. It is often paired with Ipamorelin, a selective GHS-R1a agonist, so that two complementary pathways combine: CJC-1295 prompting GH release through the GHRH receptor while Ipamorelin acts at the ghrelin receptor. The dual-pathway approach amplifies GH pulses and has become a standard protocol in growth hormone biology. Reported study endpoints include plasma GH levels, IGF-1 production, body composition, and sleep-linked GH secretion patterns.
Product Specifications
Laboratory Handling
- For long-term storage keep lyophilised vials at -20°C. Refrigerate reconstituted CJC-1295 at 2-8°C and use within 4 weeks.
- Reconstitute with bacteriostatic water, injecting slowly and gently down the vial wall, then swirl to dissolve rather than shake.
- Hold to strict aseptic technique, wiping stoppers with 70% isopropyl alcohol before each needle insertion.
- Draw single-use aliquots from the reconstituted stock, since repeated freeze-thaw cycling degrades GHRH analogue peptides.
Frequently Asked Questions
CJC-1295
5mg · £25.99